Rezultati pretraživanja
  1. Apparently, is being a "nuble" according to

  2. is the 4th most common worldwide. & are eagerly awaiting data from Novartis/Endocyte’s Ph 3 trial of Lutetium-177 PSMA-617. In our blog we discuss how this could change care:

  3. Have you seen our latest post on ? Our attended the Annual Meeting in . Read the team's views and of the and the evolving axSpA (axial Spondyloarthritis) .

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.